Glenmark Pharma expects generics to drive growth in coming years

25 Sep 2017 Evaluate

Glenmark Pharmaceuticals is expecting to achieve a significant growth in next three to four years on the back of strong pipeline of speciality and innovative products. Speciality and innovative products will comprise 30 per cent of its revenues by 2025.

The next few years will see consistent revenues and profitability without the need for inorganic growth through acquisitions. Over the last few years the company has invested significantly to mark the step-wise transition from generics to an innovation-driven organisation.

Glenmark Pharma Share Price

1938.35 19.30 (1.01%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×